Glow-in-the-Dark antibody could help surgeons spot prostate cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate; patients with small cell, neuroendocrine, and transitional cell carcinomas are not eligible * Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than 10 years as determined by treating physician * Patients with moderate to high-risk disease as defined by D' Amico risk stratification and having at least one of the following: * Prostate-specific antigen (PSA) level \> 10 ng/ml * Gleason score \>= 7 * Clinical stage \>= T2c * Any performance status on the Eastern Cooperative Oncology Group (ECOG) * Men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation * Bone scan without evidence of skeletal metastases * Skeletal x-ray film or MRI confirmation of absent skeletal metastases if bone scan findings are equivocal * 3Tesla (T) multiparametric MRI of the prostate performed at City of Hope (COH) within 6 week time period prior to surgery; MRI without evidence of bladder neck involvement, rectal wall involvement, or pelvic lymphadenopathy with no nodes \> 1 cm * White blood cell (WBC) within normal limits * Hemoglobin (hgb) \> 10 G/dL * Platelet count (PLT) \> 100 K/uL * Creatinine clearance within normal limits * Serum glutamic oxaloacetic transaminase (SGOT) \< 1.5 x upper limit of normal (ULN) * Serum glutamate pyruvate transaminase (SGPT) \< 1.5 x ULN * Bilirubin \< 1.5 x ULN * All subjects must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Patients should not have any uncontrolled illness including ongoing or active infection * Prior treatment of prostate cancer including brachytherapy, radiation therapy, cryosurgery, high-intensity focused ultrasound (HIFU), or vaccine therapy * Prior pelvic surgery or radiation * Urinary incontinence requiring condom catheter use or \>= 1 pad/day * Prior anti-incontinence surgery * Use of neoadjuvant hormonal manipulation * History of active co-existing non-prostatic malignancies except basal cell skin cancer or squamous cell skin cancer * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study